Impact of NSAID Use on Bleeding Rates for Patients Taking Rivaroxaban or Apixaban.
Bleeding rates were not significantly different between patients taking rivaroxaban and patients taking apixaban, regardless of NSAID use. A population health management tool may provide a safe approach for coprescribing NSAIDs with DOACs. Additional prospective studies are needed to quantify the comparative bleeding risk with concomitant NSAID use among DOACs alone.
Authors
- Alan Radford (ORCID: https://orcid.org/0000-0002-4590-1334)
- Rebecca Worsham (ORCID: https://orcid.org/0000-0001-7300-9864)
- R. Darren Wood (ORCID: https://orcid.org/0000-0003-4798-4249)
Institutions
- East Tennessee State University (US)
- James H. Quillen VA Medical Center (US)
Publication Details
- Journal
- PubMed
- Published
- 2024-12-01
- DOI
- https://doi.org/10.12788/fp.0540
- Citations
- 1
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.40